{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:17:45Z","timestamp":1793755065049,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1208\/s12249-020-01867-x","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T14:07:16Z","timestamp":1605708436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Contrastive Studies of Cytarabine\/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu2+ Gradient Method"],"prefix":"10.1208","volume":"21","author":[{"given":"Jiaoyang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"1867_CR1","unstructured":"Kim W, Haws H, Mangelson R, Peterson P, Whatcott C, Siddiqui-Jain A, et al. Alvocidib synergizes with cytarabine and daunorubicin (7+3) in preclinical models of acute myeloid leukemia. Haematologica. 2017;102:370."},{"issue":"4","key":"1867_CR2","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s10895-017-2070-x","volume":"27","author":"VM Trusova","year":"2017","unstructured":"Trusova VM, Deligeorgiev T, Gorbenko G. Liposomal co-encapsulation of two novel europium complexes and doxorubicin: fluorescence study. J Fluoresc. 2017;27(4):1359\u201363. https:\/\/doi.org\/10.1007\/s10895-017-2070-x.","journal-title":"J Fluoresc"},{"issue":"4","key":"1867_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/03639045.2017.1405432","volume":"44","author":"J Lei","year":"2018","unstructured":"Lei J, Cong S, Song M, Zhang W, Peng G, Li X, et al. Combination of doxorubicin with harmine-loaded liposomes exerting synergistic antitumor efficacy. Drug Dev Ind Pharm. 2018;44(4):570\u201381. https:\/\/doi.org\/10.1080\/03639045.2017.1405432.","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"1867_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.beha.2019.05.005","volume":"32","author":"JE Maakaron","year":"2019","unstructured":"Maakaron JE, Mims AS. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: a new twist on an old cocktail. Best Pract Res Clin Haematol. 2019;32(2):127\u201333. https:\/\/doi.org\/10.1016\/j.beha.2019.05.005.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8","key":"1867_CR5","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1158\/1535-7163.MCT-09-0243","volume":"8","author":"PG Tardi","year":"2009","unstructured":"Tardi PG, Dos Santos N, Harasym TO, Johnstone SA, Zisman N, Tsang AW, et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther. 2009;8(8):2266\u201375. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0243.","journal-title":"Mol Cancer Ther"},{"key":"1867_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-1-60761-416-6_13","volume":"596","author":"BD Liboiron","year":"2010","unstructured":"Harasym TO, Liboiron BD, Mayer LD. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Methods Mol Biol. 2010;596:291\u2013323. https:\/\/doi.org\/10.1007\/978-1-60761-416-6_13.","journal-title":"Methods Mol Biol"},{"key":"1867_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jconrel.2016.03.027","volume":"229","author":"KM Camacho","year":"2016","unstructured":"Camacho KM, Menegatti S, Vogus DR, Pusuluri A, Fuchs Z, Jarvis M, et al. DAFODIL: a novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy. J Control Release. 2016;229:154\u201362. https:\/\/doi.org\/10.1016\/j.jconrel.2016.03.027.","journal-title":"J Control Release"},{"key":"1867_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/2278-330X.149950","volume":"3","author":"LS Raut","year":"2015","unstructured":"Raut LS. Novel formulation of cytarabine and daunorubicin: a new hope in AML treatment. South Asian J Cancer. 2015;3:38\u201340. https:\/\/doi.org\/10.4103\/2278-330X.149950.","journal-title":"South Asian J Cancer"},{"issue":"No.7","key":"1867_CR9","first-page":"380","volume":"11","author":"IS Jensen","year":"2018","unstructured":"Jensen IS, Wu E, Sacks NC, Cyr PL, Chung KC. Budget impact analysis of using daunorubicin-cytarabine liposome in patients with newly diagnosed therapy-related AML or AML and myelodysplasia-related changes. Am Health Drug Benefits. 2018;11(No.7):380\u20136.","journal-title":"Am Health Drug Benefits"},{"issue":"No.26","key":"1867_CR10","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. Cpx-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(No.26):2684\u201392. https:\/\/doi.org\/10.1200\/JCO.2017.77.6112.","journal-title":"J Clin Oncol."},{"issue":"9","key":"1867_CR11","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","volume":"25","author":"AC Krauss","year":"2019","unstructured":"Krauss AC, Gao X, Li L, Manning ML, Patel P, Fu W, et al. FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia. Clin Cancer Res. 2019;25(9):2685\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2990.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1867_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","volume":"33","author":"P Tardi","year":"2009","unstructured":"Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33(1):129\u201339. https:\/\/doi.org\/10.1016\/j.leukres.2008.06.028.","journal-title":"Leuk Res"},{"issue":"8","key":"1867_CR13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/1060028018764923","volume":"52","author":"M Kim","year":"2018","unstructured":"Kim M, Williams S. Daunorubicin and cytarabine liposome in newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes. Ann Pharmacother. 2018;52(8):792\u2013800. https:\/\/doi.org\/10.1177\/1060028018764923.","journal-title":"Ann Pharmacother"},{"issue":"No.13","key":"1867_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s10637-012-9839-1","volume":"14","author":"AWML Tolcher","year":"2018","unstructured":"Tolcher AWML. Improving combination cancer therapy: the CombiPlex((R)) development platform. Future Oncol. 2018;14(No.13):1317\u201332. https:\/\/doi.org\/10.1007\/s10637-012-9839-1.","journal-title":"Future Oncol"},{"issue":"7","key":"1867_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.exphem.2011.04.001","volume":"39","author":"HP Kim","year":"2011","unstructured":"Kim HP, Gerhard B, Harasym TO, Mayer LD, Hogge DE. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol. 2011;39(7):741\u201350. https:\/\/doi.org\/10.1016\/j.exphem.2011.04.001.","journal-title":"Exp Hematol"},{"issue":"1\u20132","key":"1867_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ijpharm.2010.02.014","volume":"391","author":"A Dicko","year":"2010","unstructured":"Dicko A, Kwak S, Frazier AA, Mayer LD, Liboiron BD. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int J Pharm. 2010;391(1\u20132):248\u201359. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.02.014.","journal-title":"Int J Pharm"},{"issue":"1","key":"1867_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3109\/08982104.2011.627513","volume":"22","author":"X Sha","year":"2012","unstructured":"Sha X, Guo J, Chen Y, Fang X. Effect of phospholipid composition on pharmacokinetics and biodistribution of epirubicin liposomes. J Liposome Res. 2012;22(1):80\u20138. https:\/\/doi.org\/10.3109\/08982104.2011.627513.","journal-title":"J Liposome Res"},{"key":"1867_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.colsurfb.2014.09.029","volume":"123","author":"JO Eloy","year":"2014","unstructured":"Eloy JO, Claro de Souza M, Petrilli R, Barcellos JP, Lee RJ, Marchetti JM. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf B: Biointerfaces. 2014;123:345\u201363. https:\/\/doi.org\/10.1016\/j.colsurfb.2014.09.029.","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"1867_CR19","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.2147\/IJN.S139450","volume":"14","author":"LD Mayer","year":"2019","unstructured":"Mayer LD, Tardi P, Louie AC. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int J Nanomedicine. 2019;14:3819\u201330. https:\/\/doi.org\/10.2147\/IJN.S139450.","journal-title":"Int J Nanomedicine"},{"issue":"38","key":"1867_CR20","doi-asserted-by":"publisher","first-page":"15999","DOI":"10.1039\/c5nr04353k","volume":"7","author":"M Lei","year":"2015","unstructured":"Lei M, Ma M, Pang X, Tan F, Li N. A dual pH\/thermal responsive nanocarrier for combined chemo-thermotherapy based on a copper-doxorubicin complex and gold nanorods. Nanoscale. 2015;7(38):15999\u20136011. https:\/\/doi.org\/10.1039\/c5nr04353k.","journal-title":"Nanoscale."},{"issue":"No.6","key":"1867_CR21","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1021\/mp100245u","volume":"7","author":"LMM Azadeh Kheirolomoom","year":"2010","unstructured":"Azadeh Kheirolomoom LMM, Lai C-Y, Lindfors HA, Seo JW, Paoli EE, Watson KD, et al. Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity. Mol Pharm. 2010;7(No.6):1948\u201358. https:\/\/doi.org\/10.1021\/mp100245u.","journal-title":"Mol Pharm"},{"issue":"2","key":"1867_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/10428194.2019.1660970","volume":"61","author":"M Alfayez","year":"2020","unstructured":"Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. CPX-351 (vyxeos) in AML. Leuk Lymphoma. 2020;61(2):288\u201397. https:\/\/doi.org\/10.1080\/10428194.2019.1660970.","journal-title":"Leuk Lymphoma"},{"key":"1867_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ijpharm.2018.12.072","volume":"557","author":"J Liu","year":"2019","unstructured":"Liu J, Chi D, Pan S, Zhao L, Wang X, Wang D, et al. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent. Int J Pharm. 2019;557:264\u201372. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.12.072.","journal-title":"Int J Pharm"},{"key":"1867_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2017.11.007","volume":"269","author":"LM Russell","year":"2018","unstructured":"Russell LM, Hultz M, Searson PC. Leakage kinetics of the liposomal chemotherapeutic agent Doxil: the role of dissolution, protonation, and passive transport, and implications for mechanism of action. J Control Release. 2018;269:171\u20136. https:\/\/doi.org\/10.1016\/j.jconrel.2017.11.007.","journal-title":"J Control Release"},{"issue":"26","key":"1867_CR25","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1021\/ic00168a058","volume":"22","author":"H Beraldo","year":"1983","unstructured":"Beraldo H, Garnier-Suillerot A, Tosi L. Copper(II)-adriamycin complexes. A circular dichroism and resonance Raman study. Inorg Chem. 1983;22(26):4117\u201324. https:\/\/doi.org\/10.1021\/ic00168a058.","journal-title":"Inorg Chem"},{"issue":"1\u20132","key":"1867_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ijpharm.2012.04.011","volume":"430","author":"K Nakamura","year":"2012","unstructured":"Nakamura K, Yoshino K, Yamashita K, Kasukawa H. Designing a novel in vitro drug-release-testing method for liposomes prepared by pH-gradient method. Int J Pharm. 2012;430(1\u20132):381\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.04.011.","journal-title":"Int J Pharm"},{"key":"1867_CR27","doi-asserted-by":"publisher","unstructured":"Lee RJ, Wang S, Turk MJ, Low PS. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Biosci Rep. 1998;18(2):69\u201378. https:\/\/doi.org\/10.1023\/A:1020132226113.","DOI":"10.1023\/A:1020132226113"},{"issue":"4","key":"1867_CR28","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s11095-017-2097-3","volume":"34","author":"JH Kang","year":"2017","unstructured":"Kang JH, Jang WY, Ko YT. The effect of surface charges on the cellular uptake of liposomes investigated by live cell imaging. Pharm Res. 2017;34(4):704\u201317. https:\/\/doi.org\/10.1007\/s11095-017-2097-3.","journal-title":"Pharm Res"},{"issue":"No.1","key":"1867_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1359-0294(00)00090-X","volume":"6","author":"Y Barenholz","year":"2001","unstructured":"Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid Interface Sci. 2001;6(No.1):66\u201377. https:\/\/doi.org\/10.1016\/S1359-0294(00)00090-X.","journal-title":"Curr Opin Colloid Interface Sci"},{"issue":"No.2","key":"1867_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0304-4157(97)00006-3","volume":"1331","author":"PRCMJHMBBTDMLDMDB Fenske","year":"1997","unstructured":"Fenske PRCMJHMBBTDMLDMDB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta. 1997;1331(No.2):187\u2013211. https:\/\/doi.org\/10.1016\/S0304-4157(97)00006-3.","journal-title":"Biochim Biophys Acta"},{"issue":"No.2","key":"1867_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0169-409X(96)00476-0","volume":"24","author":"T Gagdhattdlas","year":"1997","unstructured":"Gagdhattdlas T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev. 1997;24(No.2):337\u201344. https:\/\/doi.org\/10.1016\/S0169-409X(96)00476-0.","journal-title":"Adv Drug Deliv Rev"},{"issue":"No.5","key":"1867_CR32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"Y GASHB","year":"2003","unstructured":"GASHB Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42(No.5):419\u201336.","journal-title":"Clin Pharmacokinet"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-01867-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-020-01867-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-01867-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T22:00:27Z","timestamp":1606255227000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-020-01867-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1867"],"URL":"https:\/\/doi.org\/10.1208\/s12249-020-01867-x","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"28 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Ethics Committee of Shenyang Pharmaceutical University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All animal experiments are in line with guidelines for the care and use of laboratory animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"325"}}